Efficacy and safety of Kangxian Huanji Granule as adjunctive treatment in acute exacerbation of idiopathic pulmonary fibrosis: An exploratory randomized controlled trial

Raghu, 2011, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med, 183, 788, 10.1164/rccm.2009-040GL Collard, 2016, Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group report, Am J Respir Crit Care Med, 194, 265, 10.1164/rccm.201604-0801CI Song, 2011, Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome, Eur Respir J, 37, 356, 10.1183/09031936.00159709 Travis, 2013, An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, Am J Respir Crit Care Med, 188, 733, 10.1164/rccm.201308-1483ST Ji, 2020, Efficacy and safety of traditional Chinese medicine in idiopathic pulmonary fibrosis: a meta-analysis, Evid Based Complement Alternat Med, 2020, 1752387, 10.1155/2020/1752387 Zhou, 2020, Yiqi Yangyin Huoxue method in treating idiopathicpulmonary fibrosis: a systematic review and meta-analysis of randomized controlled trials, Evid Based Complement Alternat Med, 2020, 8391854, 10.1155/2020/8391854 Zang, 2017, Meta-analysis on clinical effect of collaterals disease theory of traditional Chinese medicine in treating idiopathic pulmonary fibrosis, Zhonghua Zhong Yi Yao Za Zhi, 32, 3170 Zhang, 2022, Efficacy and safety of traditional Chinese medicine in patients with acute exacerbation of idiopathic pulmonary fibrosis: study protocol for randomized, controlled, exploratory clinical trial, Trials, 23, 103, 10.1186/s13063-022-06026-0 The Group of Interstitial Lung Disease of Chinese Thoracic Society. Chinese expert consensus for the diagnosis and treatment of acute exacerbation of idiopathic pulmonary fibrosis. Zhonghua Yi Xue Za Zhi 2019;99(26):2014–23 [Chinese]. Mahler, 1988, Evaluation of clinical methods for rating dyspnea, Chest, 93, 580, 10.1378/chest.93.3.580 Yorke, 2010, Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire, Thorax, 65, 921, 10.1136/thx.2010.139121 Wang, 2009 Ryerson, 2015, Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm, Eur Respir J, 46, 512, 10.1183/13993003.00419-2015 Cottin, 2017, Burden of idiopathic pulmonary fibrosis progression: a 5-year longitudinal follow-up study, PLoS One, 12, e0166462, 10.1371/journal.pone.0166462 Kishaba, 2014, Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis, Lung, 192, 141, 10.1007/s00408-013-9530-0 Di JQ, Li XL, Cao JM, Yang SG, Yu XQ. Analysis of the outcome indicators in randomized controlled trials of idiopathic pulmonary fibrosis. Zhong Yi Za Zhi 2021;62(12):1040–5 [Chinese]. Wu, 2019, Effectiveness and safety of chinese medicine for idiopathic pulmonary fibrosis: a systematic review and meta-analysis, Chin J Integr Med, 25, 778, 10.1007/s11655-017-2429-5 Guo, 2019, Chinese herbal medicines compared with N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: a systematic review of randomized controlled trials, Evid Based Complement Alternat Med, 2019, 5170638, 10.1155/2019/5170638 Papiris, 2015, Survival in idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach, BMC Pulm Med, 15, 162, 10.1186/s12890-015-0146-4 Farrand, 2020, Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF, Respirology, 25, 629, 10.1111/resp.13753 Rush, 2016, The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: a nationwide retrospective cohort analysis, Respir Med, 111, 72, 10.1016/j.rmed.2015.12.005 Oda, 2016, Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan, BMC Pulm Med, 16, 91, 10.1186/s12890-016-0253-x Suzuki, 2021, Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis: a multicentre retrospective cohort study, Sci Rep, 11, 9120, 10.1038/s41598-021-88718-2 Kondoh, 2017, Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis, Eur Respir Rev, 26, 10.1183/16000617.0050-2017 Rajala, 2017, mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis, ERJ Open Res, 3, 00084, 10.1183/23120541.00084-2017 Prior, 2019, Validation of the IPF-specific version of St. George’s Respiratory Questionnaire, Respir Res, 20, 199, 10.1186/s12931-019-1169-9 Swigris, 2010, The SF-36 and SGRQ: validity and first look at minimum important differences in IPF, Respir Med, 104, 296, 10.1016/j.rmed.2009.09.006